MEOBF
Price
$2.00
Change
-$0.50 (-20.00%)
Updated
Jan 16 closing price
Capitalization
1.99B
28 days until earnings call
MESO
Price
$17.64
Change
-$0.40 (-2.22%)
Updated
Jan 22, 04:59 PM (EDT)
Capitalization
1.99B
28 days until earnings call
Ad is loading...

MEOBF vs MESO

Header iconMEOBF vs MESO Comparison
Open Charts MEOBF vs MESOBanner chart's image
Mesoblast
Price$2.00
Change-$0.50 (-20.00%)
Volume$519.8K
Capitalization1.99B
Mesoblast
Price$17.64
Change-$0.40 (-2.22%)
Volume$4.54K
Capitalization1.99B
MEOBF vs MESO Comparison Chart
Loading...
MEOBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MESO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MEOBF vs. MESO commentary
Jan 23, 2025

To understand the difference between Mesoblast Ltd (MEOBF) vs. Mesoblast Ltd - ADR (MESO) it is enough to know the definitions of ADR

ADR - American depositary receipt (ADR) is a certificate issued by a U.S. depositary bank representing a specified number of shares (often 1 share) of a foreign company's stock. ADRs are denominated in U.S. dollars and trade on U.S. stock markets and OTC depending on the ADRs classification.

Ad is loading...
COMPARISON
Comparison
Jan 23, 2025
Stock price -- (MEOBF: $2.00 vs. MESO: $17.58)
Brand notoriety: MEOBF and MESO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MEOBF: 0% vs. MESO: 61%
Market capitalization -- MEOBF: $1.99B vs. MESO: $1.99B
MEOBF [@Biotechnology] is valued at $1.99B. MESO’s [@Biotechnology] market capitalization is $1.99B. The market cap for tickers in the [@Biotechnology] industry ranges from $355.19B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MEOBF’s FA Score shows that 0 FA rating(s) are green whileMESO’s FA Score has 0 green FA rating(s).

  • MEOBF’s FA Score: 0 green, 5 red.
  • MESO’s FA Score: 0 green, 5 red.
According to our system of comparison, MEOBF is a better buy in the long-term than MESO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MEOBF’s TA Score shows that 1 TA indicator(s) are bullish while MESO’s TA Score has 1 bullish TA indicator(s).

  • MEOBF’s TA Score: 1 bullish, 1 bearish.
  • MESO’s TA Score: 1 bullish, 5 bearish.
According to our system of comparison, MEOBF is a better buy in the short-term than MESO.

Price Growth

MEOBF (@Biotechnology) experienced а -20.00% price change this week, while MESO (@Biotechnology) price change was +2.81% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.70%. For the same industry, the average monthly price growth was +2.32%, and the average quarterly price growth was -2.48%.

Reported Earning Dates

MEOBF is expected to report earnings on May 23, 2025.

MESO is expected to report earnings on May 23, 2025.

Industries' Descriptions

@Biotechnology (+1.70% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MEOBF($1.99B) and MESO($1.99B) have the same market capitalization . MEOBF YTD gains are higher at: -9.091 vs. MESO (-11.212). MEOBF (-62.82M) and MESO (-62.82M) have comparable annual earnings (EBITDA) . MEOBF (62.6M) and MESO (62.6M) have equal amount of cash in the bank . MEOBF (119M) and MESO (119M) have identical debt. MEOBF (5.9M) and MESO (5.9M) have equivalent revenues.
MEOBFMESOMEOBF / MESO
Capitalization1.99B1.99B100%
EBITDA-62.82M-62.82M100%
Gain YTD-9.091-11.21281%
P/E RatioN/AN/A-
Revenue5.9M5.9M100%
Total Cash62.6M62.6M100%
Total Debt119M119M100%
FUNDAMENTALS RATINGS
MEOBF vs MESO: Fundamental Ratings
MEOBF
MESO
OUTLOOK RATING
1..100
9976
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
89
Overvalued
PROFIT vs RISK RATING
1..100
7887
SMR RATING
1..100
9595
PRICE GROWTH RATING
1..100
3434
P/E GROWTH RATING
1..100
6097
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MEOBF's Valuation (89) in the null industry is in the same range as MESO (89) in the Biotechnology industry. This means that MEOBF’s stock grew similarly to MESO’s over the last 12 months.

MEOBF's Profit vs Risk Rating (78) in the null industry is in the same range as MESO (87) in the Biotechnology industry. This means that MEOBF’s stock grew similarly to MESO’s over the last 12 months.

MEOBF's SMR Rating (95) in the null industry is in the same range as MESO (95) in the Biotechnology industry. This means that MEOBF’s stock grew similarly to MESO’s over the last 12 months.

MEOBF's Price Growth Rating (34) in the null industry is in the same range as MESO (34) in the Biotechnology industry. This means that MEOBF’s stock grew similarly to MESO’s over the last 12 months.

MEOBF's P/E Growth Rating (60) in the null industry is somewhat better than the same rating for MESO (97) in the Biotechnology industry. This means that MEOBF’s stock grew somewhat faster than MESO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MEOBFMESO
RSI
ODDS (%)
N/A
Bearish Trend 16 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 16 days ago
71%
Bearish Trend 16 days ago
88%
Momentum
ODDS (%)
N/A
Bearish Trend 16 days ago
86%
MACD
ODDS (%)
N/A
Bearish Trend 16 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 16 days ago
56%
Bearish Trend 16 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 16 days ago
55%
Bullish Trend 16 days ago
81%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
N/A
Bearish Trend 16 days ago
84%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bullish Trend 16 days ago
60%
Bullish Trend 16 days ago
79%
View a ticker or compare two or three
Ad is loading...
MEOBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MESO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MRGRX57.170.30
+0.53%
MFS Core Equity I
HDIVX15.940.05
+0.31%
Janus Henderson Responsible Intl Div I
ARIFX11.30N/A
N/A
Aristotle International Eq I
MXVHX6.80N/A
N/A
Empower Large Cap Value Instl
RYECX198.37-3.27
-1.62%
Rydex Energy C

MEOBF and

Correlation & Price change

A.I.dvisor indicates that over the last year, MEOBF has been loosely correlated with SPHDF. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if MEOBF jumps, then SPHDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MEOBF
1D Price
Change %
MEOBF100%
N/A
SPHDF - MEOBF
50%
Loosely correlated
N/A
AVTX - MEOBF
46%
Loosely correlated
-4.49%
COGT - MEOBF
39%
Loosely correlated
N/A
MESO - MEOBF
26%
Poorly correlated
-2.55%
KROS - MEOBF
26%
Poorly correlated
-0.18%
More

MESO and

Correlation & Price change

A.I.dvisor indicates that over the last year, MESO has been closely correlated with SAGE. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if MESO jumps, then SAGE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MESO
1D Price
Change %
MESO100%
-2.55%
SAGE - MESO
66%
Closely correlated
+1.01%
QTTB - MESO
50%
Loosely correlated
+1.18%
VTGN - MESO
48%
Loosely correlated
-0.66%
TNGX - MESO
33%
Poorly correlated
N/A
TSVT - MESO
32%
Poorly correlated
+2.86%
More